Isomorphic Labs raises $5B as it looks to take drug candidates to
In Brief Posted: 6:50 AM PST · November 17, 2026 Image Credits: Jose Sarmento Matos/Bloomberg / Getty Images Ram Iyer Isomorphic Labs raises $5B as it looks…
Summary
In Brief Posted: 6:50 AM PST · November 17, 2026 Image Credits: Jose Sarmento Matos/Bloomberg / Getty Images Ram Iyer Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials. The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capita G, Thrive Capital, MGX, Temasek, and the U. Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs.
Positives
- In Brief Posted: 6:50 AM PST · November 17, 2026 Image Credits: Jose Sarmento Matos/Bloomberg / Getty Images Ram Iyer Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.
- The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating.
- The new funding, which comes on the heels of a $2.
Risks & concerns
- The article may not provide enough evidence to validate every implication.
- Execution, cost, adoption, regulation, or security could change the outcome.